




MAY 2020 NEWSLETTER


Does early treatment with highly effective DMT improve prognosis for people with MS?

WELCOME TO THE DELIVER-MS NEWSLETTER




We hope that for some of you the pressures of COVID19 are easing somewhat and we can look forward to the return of more normal MS services soon. Please see below for guidance on COVID-19 relevant to DELIVER-MS.



Even during the COVID-19 outbreak, some people with MS will still need to start DMT. We have seen a low level of recruitment activity continue this month.





NEWS FROM THE DELIVER-MS TEAM

-  The DELIVER-MS trial was featured in an article in the Research Matters publication this month, which circulates to 35,000 people affected by MS (**see link at the foot of the email**). Plans are being hatched to follow this piece with an online article in time for International Clinical Trials Day (20th May) so look out on social media channels.
-  On advice from our Patient Advisory Committee we are undertaking several upgrades to the public-facing website including the addition of a FAQs section, and providing feedback from existing participants. Don't forget to signpost potential participants to www.deliver-ms.com.
-  Here are some tasters of responses current DELIVER-MS participants gave when we asked them why they chose to participate:

"Receiving a diagnosis can make you feel helpless. I wanted to feel I was doing something to make a difference."

"I felt the study was trying to fill a gap in the understanding of MS, so anything I can do to help bridge that gap and help future patients is a must."

FINAL THOUGHTS

-  We are hope you all stay well in the coming weeks.
 -  Do reach out to us with any questions about the running of DELIVER-MS at your site and we will be happy to advise.
-